Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an announcement.
Chimeric Therapeutics Ltd. has applied for the quotation of 733,333 new ordinary fully paid shares on the ASX, to be issued on May 1, 2026, under its existing CHM ticker. The new securities arise from the exercise or conversion of existing options or other convertible instruments, modestly increasing the company’s listed share capital and potentially broadening liquidity for current and prospective shareholders.
This incremental issuance indicates ongoing utilization of equity-based instruments within Chimeric Therapeutics’ capital structure and may reflect confidence from holders choosing to convert into ordinary stock. While relatively small in scale, the additional quoted shares could slightly enhance trading volumes and provide a marginally larger free float in the market.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is an Australia-listed biotechnology company focused on developing innovative therapeutic products, with its ordinary fully paid shares traded on the ASX under the ticker CHM. The company operates in the life sciences sector, targeting investors interested in emerging biopharmaceutical and medical research opportunities.
Average Trading Volume: 209,393
Technical Sentiment Signal: Sell
Current Market Cap: A$8.84M
Learn more about CHM stock on TipRanks’ Stock Analysis page.